JP2022548095A5 - - Google Patents

Info

Publication number
JP2022548095A5
JP2022548095A5 JP2022516379A JP2022516379A JP2022548095A5 JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5 JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5
Authority
JP
Japan
Prior art keywords
carbocyryl
heteroatoms selected
alkyl
membered
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548095A (ja
JP7874541B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058641 external-priority patent/WO2021053555A1/en
Publication of JP2022548095A publication Critical patent/JP2022548095A/ja
Publication of JP2022548095A5 publication Critical patent/JP2022548095A5/ja
Application granted granted Critical
Publication of JP7874541B2 publication Critical patent/JP7874541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516379A 2019-09-16 2020-09-16 接着分解剤及びその使用方法 Active JP7874541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901229P 2019-09-16 2019-09-16
US62/901,229 2019-09-16
PCT/IB2020/058641 WO2021053555A1 (en) 2019-09-16 2020-09-16 Glue degraders and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026067413A Division JP2026133390A (ja) 2019-09-16 2026-04-15 接着分解剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022548095A JP2022548095A (ja) 2022-11-16
JP2022548095A5 true JP2022548095A5 (cg-RX-API-DMAC7.html) 2023-09-21
JP7874541B2 JP7874541B2 (ja) 2026-06-16

Family

ID=72717893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516379A Active JP7874541B2 (ja) 2019-09-16 2020-09-16 接着分解剤及びその使用方法

Country Status (5)

Country Link
US (1) US20220363671A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031243A1 (cg-RX-API-DMAC7.html)
JP (1) JP7874541B2 (cg-RX-API-DMAC7.html)
CN (2) CN114401960B (cg-RX-API-DMAC7.html)
WO (1) WO2021053555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4259128A4 (en) * 2020-12-09 2025-04-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2022153220A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Methods for the identification of degrons
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022254362A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
US20240287573A1 (en) 2021-06-04 2024-08-29 Monte Rosa Therapeutics, Inc. E3 ligase fusion proteins for proximity detection
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
WO2023091567A1 (en) 2021-11-17 2023-05-25 Monte Rosa Therapeutics, Inc. Degron and neosubstrate identification
CN114487379A (zh) * 2022-01-17 2022-05-13 东南大学 一种用于联合检测ca125与he4的试纸条
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
CN114410607A (zh) * 2022-03-22 2022-04-29 上海威高医疗技术发展有限公司 嗜热羧酸酯酶突变体及其应用
CN116789637B (zh) * 2022-05-13 2024-08-02 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
WO2024073871A1 (en) * 2022-10-04 2024-04-11 Biofront Ltd Gspt1 degraders, compositions comprising the degrader, and methods of using the same
KR20250135228A (ko) 2023-01-09 2025-09-12 몬테 로사 테라퓨틱스 아게 Vav1의 표적 분해
PE20260307A1 (es) 2023-06-14 2026-02-11 Astrazeneca Ab Degradadores de smarca2 y usos de estos
IL325247A (en) 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
KR20260041885A (ko) 2023-07-25 2026-03-27 몬테 로사 테라퓨틱스 아게 표적화된 단백질 분해를 위한 치환된 피페리딘디온
WO2025232888A1 (en) * 2024-05-10 2025-11-13 Shanghai Degron Biomedical Technology Co., Ltd. Wee1 degraders and uses thereof
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026013578A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Combinations comprising vav1-targeting degraders
WO2026067646A1 (zh) * 2024-09-27 2026-04-02 上海美悦生物科技发展有限公司 联苯类化合物、及其药物组合物和用途
WO2026108986A1 (zh) * 2024-11-22 2026-05-28 上海美悦生物科技发展有限公司 杂环烯基类化合物、及其药物组合物和用途
WO2026120044A1 (en) 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026154063A1 (en) 2025-01-16 2026-07-23 Monte Rosa Therapeutics Ag Reverse turboid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
TWI428332B (zh) * 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
CN109153644B (zh) * 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3897631A4 (en) * 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN

Similar Documents

Publication Publication Date Title
TWI765448B (zh) Kras g12c抑制劑
JP2025508703A5 (cg-RX-API-DMAC7.html)
JP6863970B2 (ja) ヘテロ環式化合物およびそれらの使用
JP2024534187A5 (cg-RX-API-DMAC7.html)
KR102566924B1 (ko) 케모카인 수용체 조절제 및 이의 용도
JP2022505835A5 (cg-RX-API-DMAC7.html)
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
CN112154142A (zh) 整合应激通路的调节剂
JP2021501788A (ja) 統合的ストレス経路の調節剤
JP2021501790A (ja) 統合的ストレス経路の調節剤
KR102345381B1 (ko) 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
JP2021501787A (ja) 統合的ストレス経路の調節剤
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
DK3013814T3 (en) SUBSTITUTED TETRAHYDROCARBAZOL AND CARBAZOLCARBOXAMIDE COMPOUNDS WHICH CAN BE USED AS KINase INHIBITORS
JP2021501781A (ja) 統合的ストレス経路の調節剤
JP2008523041A5 (cg-RX-API-DMAC7.html)
AU2011268906A1 (en) Heteroaryl compounds and compositions as protein kinase inhibitors
JP2007534687A5 (cg-RX-API-DMAC7.html)
MX2010001677A (es) Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
RU2007108861A (ru) Трифтометилзамещенные бензамиды в качестве ингибиторов киназ
EA010393B1 (ru) Производные хинолинона
JP2005509038A5 (cg-RX-API-DMAC7.html)
KR102598246B1 (ko) Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
JP2013540114A5 (cg-RX-API-DMAC7.html)
TW201733580A (zh) Trk抑制劑抵抗性的癌治療劑